0001140361-24-003165.txt : 20240122 0001140361-24-003165.hdr.sgml : 20240122 20240122171016 ACCESSION NUMBER: 0001140361-24-003165 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240122 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240122 DATE AS OF CHANGE: 20240122 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PDS Biotechnology Corp CENTRAL INDEX KEY: 0001472091 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 264231384 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37568 FILM NUMBER: 24549679 BUSINESS ADDRESS: STREET 1: 303A COLLEGE ROAD EAST CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 800-208-3343 MAIL ADDRESS: STREET 1: 303A COLLEGE ROAD EAST CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: Edge Therapeutics, Inc. DATE OF NAME CHANGE: 20090911 8-K 1 ef20019392_8k.htm 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 22, 2024

PDS BIOTECHNOLOGY CORPORATION
(Exact Name of Registrant as Specified in Charter)

Delaware
001-37568
26-4231384



(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
303A College Road East, Princeton, NJ 08540
(Address of Principal Executive Offices, and Zip Code)
(800) 208-3343
Registrant’s Telephone Number, Including Area Code
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.00033 per share
PDSB
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐



Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.

Effective as of January 22, 2024, Lauren V. Wood, M.D. retired from her position as Chief Medical Officer of PDS Biotechnology Corporation (the “Company”). Dr. Wood’s retirement is not related to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

On January 22, 2024, the Company amended its 2019 Inducement Plan, as amended (the “Inducement Plan”) solely to increase the total number of shares of the Company’s Common Stock, par value $0.00033 per share, reserved for issuance under the Inducement Plan from 1,100,000 shares to 2,100,000 shares. The Inducement Plan, as amended, is filed as Exhibit 10.1 hereto and incorporated herein by reference.

 Item 7.01
Regulation FD Disclosure.

On January 22, 2024, the Company issued a press release announcing the retirement of Lauren V. Wood, M.D. and the appointment of Kirk V. Shepard, M.D. as Chief Medical Officer of the Company, in each case, effective as of January 22, 2024. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

The information in this Item 7.01 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference to such filing.

Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number

Description
 
 

PDS Biotechnology Corporation 2019 Inducement Plan, as amended.

Press Release, dated January 22, 2024.
104

Cover Page Interactive Data File (embedded within the Inline XBRL document).
 

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


PDS BIOTECHNOLOGY CORPORATION



By: /s/ Frank Bedu-Addo, Ph.D.
Date: January 22, 2024
Name: Frank Bedu-Addo, Ph.D.
Title: President and Chief Executive Officer



EX-10.1 2 ef20019392_ex10-1.htm EXHIBIT 10.1

Exhibit 10.1

PDS BIOTECHNOLOGY CORPORATION

2019 INDUCEMENT PLAN

Amended on January 22, 2024

SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS

The name of the plan is the PDS Biotechnology Corporation 2019 Inducement Plan (the “Plan”). The purpose of the Plan is to provide non-qualified stock options to individuals not previously employees or Non-Employee Directors of PDS Biotechnology Company (the “Company”) (or following such individuals’ bona fide period of non-employment with the Company), as an inducement material to the individuals’ entry into employment with the Company within the meaning of Rule 5635(c)(4) of the NASDAQ Listing Rules. It is anticipated that providing such persons with a direct stake in the Company’s welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company’s behalf and strengthening their desire to remain with the Company.

The following terms shall be defined as set forth below:

“Act” means the Securities Act of 1933, as amended, and the rules and regulations thereunder.

“Administrator” means either the Board or the compensation committee of the Board or a similar committee performing the functions of the compensation committee and which is comprised of not less than two Non-Employee Directors who are independent.

“Board” means the Board of Directors of the Company.

“Change of Control” means, unless otherwise provided in an Option Award Agreement:

(a) the acquisition in one or more transactions (whether by purchase, merger or otherwise) by any "Person" (as such term is used for purposes of Section 13(d) or Section 14(d) of the Exchange Act, but excluding, for this purpose, (i) the Company or its Subsidiaries, (ii) any employee benefit plan of the Company or its Subsidiaries, (iii) an entity owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company) of "Beneficial Ownership" (within the meaning of Rule 13d-3 under the Exchange Act) of more than fifty percent (50%) of the combined voting power of the Company's then outstanding voting securities (the "Voting Securities");

(b) a change in the composition of the Board such that the individuals who as of any date constitute the Board (the "Incumbent Board") cease to constitute a majority of the Board at any time during the 24-month period immediately following such date; provided, however, that if the election, or nomination for election by the Company's shareholders, of any new director was approved by a vote of at least a majority of the Incumbent Board, such new director shall be considered as a member of the Incumbent Board, and provided further that any reductions in the size of the Board that are instituted voluntarily by the Incumbent Board shall not constitute a Change of Control, and after any such reduction the "Incumbent Board" shall mean the Board as so reduced;

(c) a complete liquidation or dissolution of the Company; or

(d) the sale of all or substantially all of the Company's and its Subsidiaries' assets (determined on a consolidated basis), other than to a Person terminated for “Cause” as defined in the Option Award Agreement.

“Code” means the Internal Revenue Code of 1986, as amended, and any successor Code, and related rules, regulations and interpretations.

“Effective Date” means June 17, 2019.


Eligible Individual” means any individual who was not previously an employee or a Non-Employee Director of the Company or any of its Subsidiaries (or who has had a bona fide period of non-employment with the Company and its Subsidiaries) who is hired by the Company or one of its Subsidiaries.

“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder.

“Fair Market Value” of the Stock means, on any given date (i) if the shares of Common Stock are then listed on a national securities exchange, including the Nasdaq Global Select Market ("NASDAQ"), the closing sales price per share of Common Stock on the exchange for such date, or if no sale was made on such date on the exchange, on the last preceding day on which a sale occurred; (ii) if shares of Common Stock are not then listed on a national securities exchange but are then quoted on another stock quotation system, the closing price for the shares of Common Stock as quoted on such quotation system on such date, or if no sale was made on such date on such quotation system, on the last preceding day on which a sale was made; or (iii) if (i) and (ii) do not apply, such value as the Committee in its discretion may in good faith determine in accordance with Section 409A of the Code and the regulations thereunder (and, with respect to Incentive Stock Options, in accordance with Section 422 of the Code and the regulations thereunder.

“Non-Employee Director” means a member of the Board who is not also an employee of the Company or any Subsidiary.

“Non-Qualified Stock Option” means a stock option that is not intended to be, or does not satisfy all requirements to be, an “incentive stock option” under Section 422 of the Code.

“Option Award Agreement” means a written or electronic document setting forth the terms and provisions applicable to a Non-Qualified Stock Option granted under the Plan. Each Option Award Agreement is subject to the terms and conditions of the Plan.

“Section 409A” means Section 409A of the Code and the regulations and other guidance promulgated thereunder.

“Stock” means the common stock of the Company, par value $0.00033 per share, subject to adjustments pursuant to Section 3.

“Subsidiary” means any corporation or other entity (other than the Company) in which the Company has at least a 50 percent interest, either directly or indirectly.

SECTION 2. ADMINISTRATION OF PLAN; ADMINISTRATOR AUTHORITY TO

SELECT GRANTEES AND DETERMINE NON-QUALIFIED STOCK OPTIONS

(a) Administration of Plan. The Plan shall be administered by the Administrator.

(b) Powers of Administrator. The Administrator shall have the power and authority to grant Non-Qualified Stock Options consistent with the terms of the Plan, including the power and authority:

(i) to select the individuals to whom Non-Qualified Stock Options may from time to time be granted;

(ii) to determine the time or times of grant;

(iii) to determine the number of shares of Stock to be covered by Non-Qualified Stock Options;

(iv) to determine and modify from time to time the terms and conditions, including restrictions, not inconsistent with the terms of the Plan, of Non-Qualified Stock Options, which terms and conditions may differ among individual Non-Qualified Stock Options and grantees, and to approve the form of Option Award Agreements;


(v) to determine the exercise price shares of Stock to be covered by Non-Qualified Stock Options;

(vi) to accelerate at any time the exercisability or vesting of all or any portion of Non-Qualified Stock Options;

(vii) subject to the provisions of Section 5(b), to extend at any time the period in which a Non-Qualified Stock Option may be exercised; and

(viii) at any time to adopt, alter and repeal such rules, guidelines and practices for administration of the Plan and for its own acts and proceedings as it shall deem advisable; to interpret the terms and provisions of the Plan and any Non-Qualified Stock Option (including related written instruments); to make all determinations it deems advisable for the administration of the Plan; to decide all disputes arising in connection with the Plan; and to otherwise supervise the administration of the Plan. Provided, however, that the Administrator shall be prohibited from effecting a repricing of any outstanding Non-Qualified Stock Options without shareholder approval

All decisions and interpretations of the Administrator shall be binding on all persons, including the Company, its Subsidiaries, Plan grantees, and persons claiming rights from or through Plan grantees and shareholders of the Company.

(c) Option Award Agreement. Non-Qualified Stock Options under the Plan shall be evidenced by Option Award Agreements that set forth the terms, conditions and limitations for each Option which may include, without limitation, the term of a Non-Qualified Stock Option and the provisions applicable in the event employment or service terminates.

(d) Indemnification. Neither the Board nor the Administrator, nor any member of either or any delegate thereof, shall be liable for any act, omission, interpretation, construction or determination made in good faith in connection with the Plan, and the members of the Board and the Administrator (and any delegate thereof) shall be entitled in all cases to indemnification and reimbursement by the Company in respect of any claim, loss, damage or expense (including, without limitation, reasonable attorneys’ fees) arising or resulting therefrom to the fullest extent permitted by law and/or under the Company’s articles or bylaws or any directors’ and officers’ liability insurance coverage which may be in effect from time to time and/or any indemnification agreement between such individual and the Company.

SECTION 3. STOCK ISSUABLE UNDER THE PLAN; MERGERS; SUBSTITUTION

(a) Stock Issuable. The maximum number of shares of Stock reserved and available for issuance under the Plan shall be 2,100,000 shares (the “Initial Limit”), subject to adjustment as provided in Section 3(b). For purposes of this limitation, the shares of Stock underlying any Non-Qualified Stock Options that are forfeited, canceled, held back upon exercise of a Non-Qualified Stock Option or settlement of a Non-Qualified Stock Option to cover the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) shall be added back to the shares of Stock available for issuance under the Plan. In the event the Company repurchases shares of Stock on the open market, such shares shall not be added to the shares of Stock available for issuance under the Plan. The shares available for issuance under the Plan may be authorized but unissued shares of Stock or shares of Stock reacquired by the Company.


(b) Changes in Stock. Subject to Section 3(c) hereof, if, as a result of any reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar change in the Company’s capital stock, the outstanding shares of Stock are increased or decreased or are exchanged for a different number or kind of shares or other securities of the Company, or additional shares or new or different shares or other securities of the Company or other non-cash assets are distributed with respect to such shares of Stock or other securities, or, if, as a result of any merger or consolidation, sale of all or substantially all of the assets of the Company, the outstanding shares of Stock are converted into or exchanged for securities of the Company or any successor entity (or a parent or subsidiary thereof), the Administrator shall make an appropriate or proportionate adjustment in (i) the maximum number of shares reserved for issuance under the Plan, (ii) the number and kind of shares or other securities subject to any then outstanding Non-Qualified Stock Options under the Plan, and (iii) the exercise price for each share subject to any then outstanding Non-Qualified Stock Options, without changing the aggregate exercise price (i.e., the exercise price multiplied by the number of Non-Qualified Stock Options) as to which such Non-Qualified Stock Options remain exercisable. The Administrator shall also make equitable or proportionate adjustments in the number of shares subject to outstanding Non-Qualified Stock Options and the exercise price and the terms of outstanding Non-Qualified Stock Options to take into consideration cash dividends paid other than in the ordinary course or any other extraordinary corporate event. The adjustment by the Administrator shall be final, binding and conclusive. No fractional shares of Stock shall be issued under the Plan resulting from any such adjustment, but the Administrator in its discretion may make a cash payment in lieu of fractional shares.

(c) Mergers and Other Transactions. Except as the Administrator may otherwise specify with respect to particular Non-Qualified Stock Options in the relevant Option Award Agreement, upon the occurrence of a Change in Control, the Administrator, in its discretion, may take one or more of the following actions with respect to Non-Qualified Stock Options that are outstanding as of such Change in Control: (a) cancel any outstanding Non-Qualified Stock Options in exchange for a cash payment in an amount equal to the excess, if any, of the Fair Market Value of the Stock underlying the unexercised portion of the Non-Qualified Stock Option as of the date of the Change in Control over the exercise price or grant price, as the case may be, of such portion, provided that any Non-Qualified Stock Option with an exercise price or grant price, as the case may be, that equals or exceeds the Fair Market Value of the Stock on the date of such Change in Control shall be cancelled with no payment due the Plan grantee; (b) terminate any Non-Qualified Stock Option, effectively immediately prior to the Change in Control, provided that the Company provides the Plan grantee an opportunity to exercise such Non-Qualified Stock Option within a specified period following the Plan grantee's receipt of a written notice of such Change in Control and the Company's intention to terminate such Non-Qualified Stock Options, effective immediately prior to such Change in Control; (c) require the successor or acquiring company (or its parents or subsidiaries), following a Change in Control, to assume any outstanding Non-Qualified Stock Option and to substitute such Non-Qualified Stock Option with awards involving the common equity securities of such company on terms and conditions necessary to preserve the rights of Plan grantees with respect to such Non-Qualified Stock Options or (e) take such other actions as the Committee believes may be appropriate.

(d) Substitute Non-Qualified Stock Options. The Administrator may grant Non-Qualified Stock Options under the Plan in substitution for stock and stock based awards held by employees, directors or other key persons of another corporation in connection with the merger or consolidation of the employing corporation with the Company or a Subsidiary or the acquisition by the Company or a Subsidiary of property or stock of the employing corporation. The Administrator may direct that the substitute awards be granted on such terms and conditions as the Administrator considers appropriate in the circumstances. Any substitute Non-Qualified Stock Options granted under the Plan shall not count against the share limitation set forth in Section 3(a).

SECTION 4. ELIGIBILITY

Grantees under the Plan will be such Eligible Individuals as are selected from time to time by the Administrator in its sole discretion.

SECTION 5. NON-QUALIFIED STOCK OPTIONS

Any Non-Qualified Stock Option granted under the Plan shall be in such form as the Administrator may from time to time approve.

Non-Qualified Stock Options granted pursuant to this Plan shall be subject to the following terms and conditions and shall contain such additional terms and conditions, not inconsistent with the terms of the Plan, as the Administrator shall deem desirable.


(a) Exercise Price. The exercise price per share for the Stock covered by a Non-Qualified Stock Option shall be determined by the Administrator at the time of grant but shall not be less than 100 percent of the Fair Market Value on the date of grant.

(b) Option Term. The term of each Non-Qualified Stock Options shall be fixed by the Administrator, but no Stock Option shall be exercisable more than ten years after the date the Stock Option is granted.

(c) Exercisability; Rights of a Stockholder. Non-Qualified Stock Options shall become exercisable at such time or times, whether or not in installments, as shall be determined by the Administrator at or after the grant date. The Administrator may at any time accelerate the exercisability of all or any portion of any Non-Qualified Stock Option. A grantee shall have the rights of a stockholder only as to shares acquired upon the exercise of a Non-Qualified Stock Option and not as to unexercised Non-Qualified Stock Options.

(d) Method of Exercise. Each Option Award Agreement with respect to a Non-Qualified Stock Option shall specify the time or times at which an Non-Qualified Stock Option may be exercised in whole or in part and the terms and conditions applicable thereto, including (i) a vesting schedule (ii) whether the exercise price for a Non-Qualified Stock Option shall be paid in cash, with shares of Stock, with any combination of cash and shares of Stock, or with other legal consideration that the Administrator may deem appropriate, (iii) the methods of payment, which may include payment through cashless and net exercise arrangements, to the extent permitted by applicable law and (iv) the methods by which, or the time or times at which, Stock will be delivered or deemed to be delivered to Plan grantee upon the exercise of such Non-Qualified Stock Option. Payment of the exercise price shall in all events be made within three days after the date of exercise of an Option. With respect to any Plan grantee who is subject to Section 16 of the Exchange Act, such Plan grantee may direct the Company to reduce the number of shares that would otherwise be deliverable upon the exercise of his or her Non-Qualified Stock Option having a Fair Market Value on the date of exercise equal to the exercise price of the portion of the Non-Qualified Stock Option then being exercised.

SECTION 6. TRANSFERABILITY

(a) Transferability. Except as provided in Section 6(b) below, during a grantee’s lifetime, his or her Non-Qualified Stock Options shall be exercisable only by the grantee, or by the grantee’s legal representative or guardian in the event of the grantee’s incapacity. No Non-Qualified Stock Options shall be sold, assigned, transferred or otherwise encumbered or disposed of by a grantee other than by will or by the laws of descent and distribution or pursuant to a domestic relations order. No Non-Qualified Stock Options shall be subject, in whole or in part, to attachment, execution, or levy of any kind, and any purported transfer in violation hereof shall be null and void.

(b) Administrator Action. Notwithstanding Section 6(a), the Administrator, in its discretion, may provide either in the Option Award Agreement regarding a given Non-Qualified Stock Option or by subsequent written approval that the grantee may transfer his or her Non-Qualified Stock Options to his or her immediate family members, to trusts for the benefit of such family members, or to partnerships in which such family members are the only partners, provided that the transferee agrees in writing with the Company to be bound by all of the terms and conditions of this Plan and the applicable Non-Qualified Stock Option. In no event may a Non-Qualified Stock Option be transferred by a grantee for value.

(c) Family Member. For purposes of Section 6(b), “family member” shall mean a grantee’s child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the grantee’s household (other than a tenant of the grantee), a trust for the benefit of such family members and to partnerships in which such family members are the only partners (any vesting conditions shall be unaffected by such transfer).

(d) Designation of Beneficiary. Each grantee to whom a Non-Qualified Stock Option has been made under the Plan may designate a beneficiary or beneficiaries to exercise any Non-Qualified Stock Option or receive any payment under any Non-Qualified Stock Option payable on or after the grantee’s death. Any such designation shall be on a form provided for that purpose by the Administrator and shall not be effective until received by the Administrator. If no beneficiary has been designated by a deceased grantee, or if the designated beneficiaries have predeceased the grantee, the beneficiary shall be the grantee’s estate.


SECTION 7. TAX WITHHOLDING

(a) Payment by Grantee. Each grantee shall, no later than the date as of which the value of a Non-Qualified Stock Option or of any Stock or other amounts received thereunder first becomes includable in the gross income of the grantee for Federal income tax purposes, pay to the Company, or make arrangements satisfactory to the Administrator regarding payment of, any Federal, state, or local taxes of any kind required by law to be withheld by the Company with respect to such income. The Company and its Subsidiaries shall, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to the grantee. The Company’s obligation to deliver evidence of book entry (or stock certificates) to any grantee is subject to and conditioned on tax withholding obligations being satisfied by the grantee.

(b) Payment in Stock. Subject to approval by the Administrator, a grantee may elect to have the Company’s minimum required tax withholding obligation satisfied, in whole or in part, by authorizing the Company to withhold from shares of Stock to be issued pursuant to any Non-Qualified Stock Option a number of shares with an aggregate Fair Market Value (as of the date the withholding is effected) that would satisfy the withholding amount due.

SECTION 8. SECTION 409A AWARDS

To the extent that any Non-Qualified Stock Option is determined to constitute “nonqualified deferred compensation” within the meaning of Section 409A (a “409A Award”), the Non-Qualified Stock Option shall be subject to such additional rules and requirements as specified by the Administrator from time to time in order to comply with Section 409A. In this regard, if any amount under a 409A Award is payable upon a “separation from service” (within the meaning of Section 409A) to a grantee who is then considered a “specified employee” (within the meaning of Section 409A), then no such payment shall be made prior to the date that is the earlier of (i) six months and one day after the grantee’s separation from service, or (ii) the grantee’s death, but only to the extent such delay is necessary to prevent such payment from being subject to interest, penalties and/or additional tax imposed pursuant to Section 409A. Further, the settlement of any such Non-Qualified Stock Option may not be accelerated except to the extent permitted by Section 409A.

SECTION 9. TRANSFER, LEAVE OF ABSENCE, ETC.

For purposes of the Plan, the following events shall not be deemed a termination of employment:

(a) a transfer to the employment of the Company from a Subsidiary or from the Company to a Subsidiary, or from one Subsidiary to another; or

(b) an approved leave of absence for military service or sickness, or for any other purpose approved by the Company, if the employee’s right to re-employment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise so provides in writing.

SECTION 10. AMENDMENTS AND TERMINATION

The Board may, at any time, amend or discontinue the Plan and the Administrator may, at any time, amend or cancel any outstanding Non-Qualified Stock Option for the purpose of satisfying changes in law or for any other lawful purpose, but no such action shall adversely affect rights under any outstanding Non-Qualified Stock Option without the holder’s consent. Except as provided in Section 3(c) or 3(d), without prior stockholder approval, in no event may the Administrator exercise its discretion to reduce the exercise price of outstanding Non-Qualified Stock Options or effect repricing through cancellation and re-grants or cancellation of Non-Qualified Stock Options in exchange for cash. To the extent required under the rules of any securities exchange or market system on which the Stock is listed, Plan amendments shall be subject to approval by the Company stockholders entitled to vote at a meeting of stockholders. Nothing in this Section 10 shall limit the Administrator’s authority to take any action permitted pursuant to Section 3(c) or 3(d).


SECTION 11. STATUS OF PLAN

With respect to the portion of any Non-Qualified Stock Option that has not been exercised and any payments in cash, Stock or other consideration not received by a grantee, a grantee shall have no rights greater than those of a general creditor of the Company unless the Administrator shall otherwise expressly determine in connection with any Non-Qualified Stock Option or Non-Qualified Stock Options. In its sole discretion, the Administrator may authorize the creation of trusts or other arrangements to meet the Company’s obligations to deliver Stock or make payments with respect to Non-Qualified Stock Options hereunder, provided that the existence of such trusts or other arrangements is consistent with the foregoing sentence.

SECTION 12. GENERAL PROVISIONS

(a) No Distribution. The Administrator may require each person acquiring Stock pursuant to a Non-Qualified Stock Option to represent to and agree with the Company in writing that such person is acquiring the shares without a view to distribution thereof.

(b) Delivery of Stock Certificates. Stock certificates to grantees under this Plan shall be deemed delivered for all purposes when the Company or a stock transfer agent of the Company provides electronic evidence of book entry (or stock certificates) to any grantee. Uncertificated Stock shall be deemed delivered for all purposes when the Company or a Stock transfer agent of the Company shall have given to the grantee by electronic mail (with proof of receipt), notice of issuance and recorded the issuance in its records (which may include electronic “book entry” records). Notwithstanding anything herein to the contrary, the Company shall not be required to issue or deliver any certificates evidencing shares of Stock pursuant to the exercise of any Non-Qualified Stock Option, unless and until the Administrator has determined, with advice of counsel (to the extent the Administrator deems such advice necessary or advisable), that the issuance and delivery of such certificates is in compliance with all applicable laws, regulations of governmental authorities and, if applicable, the requirements of any exchange on which the shares of Stock are listed, quoted or traded. All Stock certificates delivered pursuant to the Plan shall be subject to any stop-transfer orders and other restrictions as the Administrator deems necessary or advisable to comply with federal, state or foreign jurisdiction, securities or other laws, rules and quotation system on which the Stock is listed, quoted or traded. The Administrator may place legends on any Stock certificate to reference restrictions applicable to the Stock. In addition to the terms and conditions provided herein, the Administrator may require that an individual make such reasonable covenants, agreements, and representations as the Administrator, in its discretion, deems necessary or advisable in order to comply with any such laws, regulations, or requirements. The Administrator shall have the right to require any individual to comply with any timing or other restrictions with respect to the settlement or exercise of any Non-Qualified Stock Option, including a window-period limitation, as may be imposed in the discretion of the Administrator.

(c) Stockholder Rights. Until Stock is deemed delivered in accordance with Section 12(b), no right to vote or receive dividends or any other rights of a stockholder will exist with respect to shares of Stock to be issued in connection with a Non-Qualified Stock Option, notwithstanding the exercise of a Non-Qualified Stock Option or any other action by the grantee with respect to a Non-Qualified Stock Option.

(d) Other Compensation Arrangements; No Employment Rights. Nothing contained in this Plan shall prevent the Board from adopting other or additional compensation arrangements, including trusts, and such arrangements may be either generally applicable or applicable only in specific cases. The adoption of this Plan and the grant of Non-Qualified Stock Options do not confer upon any employee any right to continued employment with the Company or any Subsidiary.

(e) Trading Policy Restrictions. Option exercises and other Non-Qualified Stock Options under the Plan shall be subject to the Company’s insider trading policies and procedures, as in effect from time to time.

(f) Company Documents and Policies. This Plan and all Non-Qualified Stock Options granted hereunder are subject to the corporate articles and by-laws of the Company, as they may be amended from time to time, and all other Company policies duly adopted by the Board or the Administrator and as in effect from time to time regarding the acquisition, ownership or sale of Stock by employees, including without limitation policies intended to limit the potential for insider trading and to avoid or recover compensation payable or paid on the basis of inaccurate financial results or statements, employee conduct, and other similar events.


SECTION 13. EFFECTIVE DATE OF PLAN

This Plan shall become effective upon the Effective Date.

SECTION 14. GOVERNING LAW

This Plan and all Non-Qualified Stock Options and actions taken thereunder shall be governed by, and construed in accordance with, the laws of the State of Delaware, applied without regard to conflict of law principles.



EX-99.1 3 ef20019392_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer

Board-certified oncologist and hematologist brings over 30 years of medical affairs, clinical operations leadership and commercialization experience to the Company

PRINCETON, N.J., January 22, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “the Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell activating platforms, today announced the appointment of Kirk V. Shepard, M.D., as Chief Medical Officer, effective January 22, 2024. Dr. Shepard succeeds Lauren V. Wood, M.D., who is retiring from the Company after five years in the role. Dr. Wood will continue to be available to PDS Biotech during a handover period to facilitate the transition of the role to Dr. Shepard. “We are pleased to welcome Kirk to the PDS Biotech team. His wealth of oncology and clinical expertise will be invaluable as we transition from a focus on clinical development research to regulatory strategy and commercialization for our lead targeted cancer immunotherapy candidates,” said Frank Bedu-Addo, Ph.D., President and Chief Executive Officer of PDS Biotech. “We wish to thank Dr. Wood for her invaluable contributions to PDS Biotech’s clinical development progress over the past five years. Her guidance was instrumental in the evolution of our clinical pipeline, including our Versamune® platform and antibody drug conjugate PDS01ADC. I have enjoyed working very closely with Lauren, and we wish her all the best in her retirement from PDS Biotech.”

Dr. Shepard is a board-certified medical oncologist and hematologist with more than 30 years of experience in the pharmaceutical industry. His experience spans multiple therapeutic areas and includes operational and strategic product development from Phases 1 through 4 and diverse disciplines of medical affairs and product commercialization. Prior to joining PDS Biotech, Dr. Shepard was Chief Medical Officer, Senior Vice President and Head of the Global Medical Affairs Oncology Business Group at Eisai Pharmaceutical Company. He served as President of the Medical Affairs Professional Society from 2016 to 2017. Dr. Shepard previously held leadership roles including Senior Vice President & Head, Global Medical Affairs at Baxter International Inc., Senior Vice President, Global Medical Affairs at Takeda Pharmaceuticals International and Vice President, Clinical and Scientific Affairs at Boehringer Ingelheim Pharmaceuticals, Inc.

Before his pharmaceutical industry career, Dr. Shepard served as a staff physician in the Department of Hematology and Medical Oncology at the Cleveland Clinic Foundation, where he supervised numerous studies in oncology and symptom control. He has been published in more than 50 medical publications. Dr. Shepard holds a bachelor’s degree from Cornell University and earned his medical degree from the University of Cincinnati Medical School. He completed his internship and internal medicine residency at Case Western Reserve University and fellowships in hematology and oncology at the University of Chicago Hospitals and Clinics.

“I’m excited to contribute to the development of PDS Biotech’s targeted immunotherapies which have generated impressive data underscoring their potential to revolutionize the treatment of cancer,” said Dr. Shepard. “I look forward to working with the team to advance PDS Biotech’s promising pipeline toward commercialization.”

The Company also announced today that on January 22, 2024, PDS Biotech granted nonstatutory stock options to Kirk Shepard, the Company’s new Chief Medical Officer, to purchase a total of 200,000 shares of the Company’s common stock as a material inducement to Dr. Shepard’s employment with PDS Biotech and in accordance with Nasdaq Listing Rule 5635(c)(4) and PDS Biotech’s 2019 Inducement Plan, as amended, which was adopted on June 17, 2019 and provides for the granting of equity awards to new employees of PDS Biotech.

The stock option has an exercise price of $4.49, the closing price of PDS Biotech’s common stock on January 22, 2024. The stock option vests over a four-year period, with one-quarter of the shares vesting on the first anniversary of the grant date and the remaining shares vesting monthly over the 36-month period thereafter, subject to continued employment with the company through the applicable vesting dates.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our proprietary Versamune®, Versamune® plus PDS01ADC and Infectimune® T cell-activating platforms. We believe our targeted immunotherapies have the potential to overcome the limitations of current immunotherapy approaches through the activation of the right type, quantity and potency of T cells. To date, our lead Versamune® clinical candidate, PDS0101, has demonstrated the ability to reduce and shrink tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a broad range of HPV16-associated cancers in multiple Phase 2 clinical trials and plan to advance into a Phase 3 clinical trial in combination with KEYTRUDA® for the treatment of recurrent/metastatic HPV16-positive head and neck cancer in the first quarter 2024. Our Infectimune® based vaccines have also demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses, including long-lasting memory T cell responses in pre-clinical studies to date. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0203 and other Versamune® and Infectimune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS0203 and other Versamune® and Infectimune® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; the Company’s ability to continue as a going concern; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. 

Versamune® and Infectimune® are registered trademarks of PDS Biotechnology. KEYTRUDA® is a registered trademark of Merck Sharp and Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, N.J., USA.

Investor Relations:
Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: pdsb@cg.capital

Media Contact:
Gina Cestari
6 Degrees
Phone: +1 (917) 797-7904
Email: gcestari@6degreespr.com



EX-101.SCH 4 pdsb-20240122.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 pdsb-20240122_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 6 pdsb-20240122_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Document and Entity Information
Jan. 22, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 22, 2024
Entity File Number 001-37568
Entity Registrant Name PDS BIOTECHNOLOGY CORPORATION
Entity Central Index Key 0001472091
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 26-4231384
Entity Address, Address Line One 303A College Road East
Entity Address, City or Town Princeton
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08540
City Area Code 800
Local Phone Number 208-3343
Title of 12(b) Security Common Stock, par value $0.00033 per share
Trading Symbol PDSB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
XML 8 ef20019392_8k_htm.xml IDEA: XBRL DOCUMENT 0001472091 2024-01-22 2024-01-22 false 0001472091 8-K 2024-01-22 PDS BIOTECHNOLOGY CORPORATION DE 001-37568 26-4231384 303A College Road East Princeton NJ 08540 800 208-3343 false false false false Common Stock, par value $0.00033 per share PDSB NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 22 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://pdsbiotech.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ef20019392_8k.htm pdsb-20240122.xsd pdsb-20240122_lab.xml pdsb-20240122_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ef20019392_8k.htm": { "nsprefix": "pdsb", "nsuri": "http://pdsbiotech.com/20240122", "dts": { "inline": { "local": [ "ef20019392_8k.htm" ] }, "schema": { "local": [ "pdsb-20240122.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "labelLink": { "local": [ "pdsb-20240122_lab.xml" ] }, "presentationLink": { "local": [ "pdsb-20240122_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 29, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://pdsbiotech.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20240122to20240122", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20019392_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240122to20240122", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20019392_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001140361-24-003165-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-24-003165-xbrl.zip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end